AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9876959
Drug: eptastigmine 15
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: eptastigmine 15 mg t.i.d.
Trial: 9876959
Drug: eptastigmine 10
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: eptastigmine 10 mg t.i.d.
Trial: 9876959
Drug: eptastigmine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eptastigmine (both doses) in severely impaired patients (n=222)
Trial: 7907054
Drug: PGE2 tablets
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 tablets (n = 106)
Trial: 7011011
Drug: Ibuprofen (Motrin)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (Motrin)
Trial: 19405015
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with infliximab (administered at weeks 4, 6, 10, and then every 6 weeks)
Trial: 19405015
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment with infliximab (administered at weeks 4, 6, 10 and then upon symptom recurrence)
Trial: 17316832
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 5 days post-operatively
Trial: 17316832
Drug: Ciprodex treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprodex treatment
Trial: 2883488
Drug: Chloroquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (300 mg base weekly)
Trial: 9645872
Drug: Primaquine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (0.5 mg base/kg daily)
Trial: 7837323
Drug: i.v. Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. Tramadol (1 mg/Kg)
Trial: 7837323
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water (20 ml) - Control group
Trial: 2967164
Drug: Combined beta‐agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined beta‐agonist and anticholinergic preparation (fenoterol hydrobromide 200 micrograms and ipratropium bromide 80 micrograms)
Trial: 29187242
Drug: Therapeutic cooling
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cooling plus best medical treatment
Trial: 9425972
Drug: Mepivacaine (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (1.4 mg/kg in 40 mL)
Trial: 30043250
Drug: Headache scores
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headache scores at 4 h post-dose
Trial: 30043250
Drug: Headache scores
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headache scores at 2 h post-dose
Trial: 15352918
Drug: Amitriptyline (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (80 mg)
Trial: 7491877
Drug: Fluoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40 mg)
Trial: 8304306
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine at 8:30 AM
Trial: 8304306
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine at 10 PM
Trial: 2724250
Drug: 5 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/m2 oral weekly methotrexate (MTX)
Trial: 2724250
Drug: 10 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/m2 oral weekly methotrexate (MTX)
Trial: 29390150
Drug: RV1 (monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV1 (monovalent rotavirus vaccine)
Trial: 24675993
Drug: Ethanol lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol lock therapy (E-Lock)
Trial: 18042505
Drug: Low-dose salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose salmon oil (1 g tid for 24 weeks)
Trial: 18042505
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to salmon oil treatment (from CT-SO to SO)
Trial: 18042505
Drug: Low-dose salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose salmon oil (3 g/day)
Trial: 17065044
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamins A 1000 IU, B6 2.2 mg, B12 2.2 microg, C 200 mg, E 400 IU, folic acid 400 microg, N-acetylcysteine 200 mg, Cu 2 mg, Zn 15 mg, Mn 0.5 mg, Fe 30 mg, calcium 800 mg, selenium 100 microg)
Trial: 17065044
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Fe 30 mg and folic acid 400 microg)
Trial: 12562405
Drug: Recruitment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment group (pressure-controlled stepwise increase in PEEP up to 15 cmH2O and tidal volumes of up to 18 ml x kg(‐1) for 10 cycles)
Trial: 10365012
Drug: Test 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 2: Detection of end-tidal carbon dioxide in the oral cavity
Trial: 8713637
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Xylocaine 1 mg.Kg‐1 followed by Propofol 2 mg.Kg‐1 over 20 seconds
Trial: 8713637
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Xylocaine 1 mg.Kg‐1 and Fentanyl 1.5 ug.Kg‐1 followed by Propofol 2 mg.Kg‐1 over 20 seconds
Trial: 8713637
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 ug.Kg‐1 with Propofol 2 mg.Kg‐1
Trial: 2051364
Drug: Post-treatment performance
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment performance scores at 60 months
Trial: 6343091
Drug: Misonidazole (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole (1.3 g/m2, administered 4 hr before the first 9 irradiations)
Trial: 31355956
Drug: Voriconazole +
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole + Anidulafungin (combination therapy)
Trial: 31355956
Drug: Voriconazole +
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole + Placebo (monotherapy)
Trial: 25944414
Drug: Mepivacaine-tramadol combination
RxNorm normalized name: mepivacaine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine-tramadol combination (1.3 mL of 2% mepivacaine with epinephrine 1:100,000 plus 0.5 mL of tramadol 50 mg/mL)
Trial: 25944414
Drug: Mepivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine alone (1.8 mL of 2% mepivacaine with epinephrine 1:100,000)
Trial: 25944414
Drug: Mepivacaine-tramadol combination
RxNorm normalized name: mepivacaine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine-tramadol combination
Trial: 23038043
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg eszopiclone
Trial: 23038043
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg eszopiclone
Trial: 23038043
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg eszopiclone (multiple-dose)
Trial: 12127923
Drug: Extended dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dalteparin treatment (5000 or 7500 IU.12h(‐1) to day 90)
Trial: 12127923
Drug: Extended dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dalteparin treatment
Trial: 12127923
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment with dalteparin (120 IU/kg(‐1) 12h(‐1) for 5-7 days)
Trial: 7594324
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily for 8 weeks (gastric ulcers) or 6 weeks (duodenal ulcers)
Trial: 7594324
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily for 8 weeks (gastric ulcers) or 6 weeks (duodenal ulcers) plus amoxicillin 2 g daily for 2 weeks
Trial: 2041279
Drug: Captopril (C)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (C) 50 mg
Trial: 2041279
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ID) 10 mg
Trial: 2041279
Drug: Nifedipine (N)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (N) 20 mg
Trial: 18499588
Drug: Transdermal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oxygen delivery using 2 EpiFlo oxygen generators providing oxygen at 6 mL/h into an occlusive wound dressing
Trial: 16814669
Drug: Acadesine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine (0.1 mg/kg/min; 7 h intravenous infusion and in cardioplegia solution at 5 microg/ml)
Trial: 14635629
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies that are less efficacious but more affordable and feasible than the best current therapeutic standard
Trial: 8883528
Drug: iodixanol‐270 (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol‐270 (270 mg I/ml)
Trial: 8883528
Drug: iodixanol‐320 (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol‐320 (320 mg I/ml)
Trial: 8883528
Drug: iohexol‐300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol‐300 (300 mg I/ml)
Trial: 1578612
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam 4 mg
Trial: 1578612
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam 4.5 mg
Trial: 1578612
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam 5 mg
Trial: 1578612
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of midazolam
Trial: 29667199
Drug: Multisensory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory stimulation (MSS) for 4 weeks, 3 sessions weekly, 25 minutes each session
Trial: 30541483
Drug: FaME exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FaME exercise programme, 1 hour weekly for 12 weeks, advised to exercise at home for an additional 2 hours
Trial: 27082062
Drug: Dovitinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib (500 mg/day, 5 days on, 2 days off; n = 82)
Trial: 27082062
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg twice daily; n = 83)
Trial: 23441902
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical calcipotriol, NB-UVB, and betamethasone therapies
Trial: 23441902
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NB-UVB and topical calcipotriol
Trial: 22612071
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg in 100 mL 0.9% saline, as IV infusion 30 minutes before contrast medium administration)
Trial: 18044544
Drug: DBP exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBP exposure in rats (oral gavage)
Trial: 14975457
Drug: COX‐2 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitors
Trial: 14975457
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with aspirin and other COX inhibitors
Trial: 11524482
Drug: 100-mg Dilantin
RxNorm normalized name: phenytoin sodium 100 MG [Dilantin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg Dilantin Kapseals after an 8-hour fast
Trial: 11524482
Drug: 100-mg Dilantin
RxNorm normalized name: phenytoin sodium 100 MG [Dilantin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg Dilantin Kapseals after a high-fat meal
Trial: 9272803
Drug: Sucrose alone
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose alone (0.05 ml of 24% sucrose placed on the anterior surface of the tongue just prior to heelstick)
Trial: 9272803
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sucrose and simulated rocking
Trial: 9272803
Drug: Placebo (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.05 ml sterile water administered just prior to heelstick)
Trial: 7506742
Drug: Gabexate mesilate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate, administered within 72 hours of onset of symptoms at a dose of 3 g/24 h
Trial: 26983099
Drug: Short-term interactive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term interactive video games (eight 30-minute sessions) in addition to traditional rehabilitation treatment
Trial: 26983099
Drug: Traditional rehabilitation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional rehabilitation treatment
Trial: 21883997
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg o.d.
Trial: 9174677
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg b.i.d.
Trial: 16765526
Drug: 21‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg nicotine patch for 3 months, with a 1‐month taper
Trial: 12466693
Drug: Bromelain 300
RxNorm normalized name: Bromelain
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain 300 mg t.i.d.
Trial: 11548225
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg t.i.d.
Trial: 9523811
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg mivacurium in divided doses (0.15 mg/kg followed by 0.1 mg/kg 30 s later)
Trial: 9523811
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg rocuronium
Trial: 9523811
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg mivacurium
Trial: 8089666
Drug: Bromocriptine (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (52 mg/day for 2.7 years) followed by levodopa (471 mg/day)
Trial: 8089666
Drug: Levodopa alone
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa alone (569 mg/day)
Trial: 31221502
Drug: ACT-541468 25
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-541468 25 mg
Trial: 31221502
Drug: ACT-541468 25
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-541468 25 mg and 75 mg
Trial: 31221502
Drug: ACT-541468 10
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-541468 10 mg
Trial: 31221502
Drug: ACT-541468 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-541468 (all doses)
Trial: 19890022
Drug: Simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin plus Metformin (SM)
Trial: 21865358
Drug: Simvastatin (S)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (S) and Simvastatin plus Metformin (SM)
Trial: 21865358
Drug: Simvastatin (S),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (S), Metformin (M), Simvastatin plus Metformin (SM)
Trial: 17407630
Drug: Selegiline ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline ODT 2.5 mg
Trial: 17407630
Drug: Selegiline ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline ODT 1.25 mg
Trial: 15342804
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus breast irradiation (subgroup analysis for T1, receptor-positive tumors)
Trial: 15342804
Drug: Tamoxifen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen alone (subgroup analysis for T1, receptor-positive tumors)
Trial: 15545529
Drug: Single RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single RF treatment (1 treatment)
Trial: 15545529
Drug: Two RF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two RF treatments (2 treatments spaced 1 month apart)
Trial: 9377992
Drug: Dipyrone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (1 g/100 ml NaCl i.v.)
Trial: 9377992
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml NaCl i.v.)
Trial: 8394864
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine with immune globulin (5 mL)
Trial: 10195783
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine alone
Trial: 3732422
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (30 mg/kg, once a week for 6 weeks)
Trial: 3732422
Drug: Oral maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral maintenance corticosteroid therapy (not specified)
Trial: 27788696
Drug: Mealtime intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mealtime intervention with weekly visits from a trained volunteer who prepared and shared a meal
Trial: 8681491
Drug: F105 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F105 (100 mg/m2)
Trial: 8681491
Drug: F105 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F105 (500 mg/m2)
Trial: 8681491
Drug: F105 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F105 (both doses)
Trial: 8681491
Drug: F105 (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F105 (bolus dose every 21 days)
Trial: 6422096
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy of nonspecific and host mediate immunotherapy and chemotherapy as an adjuvant to surgery
Trial: 22113220
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Group A)
Trial: 24102165
Drug: GaAs laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAs laser therapy (peak power 10 W; pulse frequency 3000 Hz; average power 0.012 W; wavelength 980 nm; irradiation duration 300 sec; dose 12.73 J/cm²)
Trial: 17032921
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy after relapse
Trial: 15326083
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 to 8 mg per day)
Trial: 15326083
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg per day)
Trial: 12002730
Drug: Fexofenadine 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 360 mg
Trial: 10417497
Drug: Promethazine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 30 mg
Trial: 9619533
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of gonadotrophins
Trial: 9619533
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of gonadotrophins
Trial: 9619533
Drug: Both s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both s.c. and i.m. administration of gonadotrophins
Trial: 7613555
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg b.i.d.)
Trial: 7613555
Drug: Doxofylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxofylline (400 mg t.i.d.)
Trial: 2198208
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg after the evening meal (R-P group)
Trial: 6282482
Drug: ACE (Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE (Doxorubicin 45 mg/m2 i.v. day 1, Cyclophosphamide 1.0 mg/m2 i.v. day 1, VP16-213 50 mg/m2/day i.v. days 1-5)